LED Medical Inc. Announces New Brand Initiative and Logo for Operating Subsidiary, LED Dental Ltd.
BURNABY, British Columbia April 2, 2014 - LED Medical Diagnostics Inc. ("LED Medical" or the "Company") announced today that its wholly-owned operating subsidiary, LED Dental Ltd. ("LED Dental") has released a new brand initiative to further its goal of providing advanced imaging technologies to dental and specialty practices in the United States and Canada. LED Dental has launched a new product division known as "LED Imaging" to reflect the subsidiary's movement further into the dental imaging category. This news comes shortly on the heels of LED Dental's recent expansions of its senior leadership team, including appointing key industry leaders Lamar Roberts and Dr. Jeffrey Brooks to the positions of president and vice president of imaging, respectively.
The branding initiative will include a new logo to further unify the business under the LED Imaging name. Backed by an experienced senior leadership team, led by Dr. David Gane, LED Imaging is dedicated to a premium level of service and support before, during and after products are sold.
"Our number one goal is to provide practitioners with best-in-class imaging technology and the service and support they deserve," said Dr. Jeffrey Brooks. "Our customers can expect a hassle-free experience when it comes to the purchase, installation and support of our products we're going to be there for them every step of the way."
In addition to its entrance into new imaging product categories, LED Dental will remain committed to the success and further development of its award-winning VELscope® Vx Enhanced Oral Assessment System. The VELscope® Vx is the worlds most frequently used adjunctive technology when screening for oral mucosal tissue anomalies, including early stage oral cancer and pre-cancer. Since launching in 2006, there have been more than 12,000 units sold and 25 million scans completed. Recently, the VELscope® Vx was used by the Seattle Mariners Major League Baseball® (MLB®) team to screen the team's players for oral cancer during spring training.
"We're very excited about our new commitment to an expanded portfolio of digital imaging technologies and we're looking forward to the bright future that lies ahead," said Lamar Roberts. "Our new brand initiative, logo and upcoming product launches further demonstrate our dedication to becoming a leading player in the dental industry."
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.
Through its wholly?owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope® Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, call 604.434.4614 or visit www.leddental.com.
Seattle Mariners, Major League Baseball, MLB and VELscope Vx are registered trademarks owned by their respective companies.
For media or investor relations inquiries, please contact:
Forward Looking Statement
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future distribution strategy and product offerings and the potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies to the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2012. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.